Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Basal Cell Carcinoma

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Basal Cell Carcinoma

Brianna McDaniel et al.
Free Books & Documents

Excerpt

Basal cell carcinoma (BCC), previously known as basal cell epithelioma, is the most common cancer in Humans. BCC mostly arises on sun-damaged skin and rarely develops on the mucous membranes or palms and soles. Basal cell carcinoma is usually a slow-growing tumor for which metastases are rare. Although rarely fatal, BCC can be highly destructive and disfigure local tissues when treatment is inadequate or delayed. On clinical examination, BCC usually appears as flesh- or pink-colored, pearly papules with overlying ulceration or telangiectatic vessels. BCC occurs on the head or neck in the majority of cases, but can involve the trunk and extremities.

More than 26 different subtypes of BCC appear in the literature, but the more common, distinctive, clinicopathologic types include: nodular, micronodular, superficial, morpheaform, infiltrative and fibroepithelial (also known as fibroepithelioma of Pinkus). Combinations of these types can occur as well. The majority of BCCs are amelanotic, but variable amounts of melanin may be present within these tumors.

The current mainstay of BCC treatment involves surgical modalities such as excision, electrodesiccation and curettage (EDC), cryosurgery, and Mohs micrographic surgery. Such methods are typically reserved for localized BCC and offer high 5-year cure rates, generally over 95%.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Brianna McDaniel declares no relevant financial relationships with ineligible companies.

Disclosure: Robert Steele declares no relevant financial relationships with ineligible companies.

Similar articles

References

    1. Dai J, Lin K, Huang Y, Lu Y, Chen WQ, Zhang XR, He BS, Pan YQ, Wang SK, Fan WX. Identification of critically carcinogenesis-related genes in basal cell carcinoma. Onco Targets Ther. 2018;11:6957-6967. - PMC - PubMed
    1. De Giorgi V, Savarese I, Gori A, Scarfi F, Topa A, Trane L, Portelli F, Innocenti A, Covarelli P. Advanced basal cell carcinoma: when a good drug is not enough. J Dermatolog Treat. 2020 Sep;31(6):552-553. - PubMed
    1. Kamath P, Darwin E, Arora H, Nouri K. A Review on Imiquimod Therapy and Discussion on Optimal Management of Basal Cell Carcinomas. Clin Drug Investig. 2018 Oct;38(10):883-899. - PubMed
    1. Martens MC, Seebode C, Lehmann J, Emmert S. Photocarcinogenesis and Skin Cancer Prevention Strategies: An Update. Anticancer Res. 2018 Feb;38(2):1153-1158. - PubMed
    1. Al Wohaib M, Al Ahmadi R, Al Essa D, Maktabbi A, Khandekar R, Al Sharif E, Al Katan H, Schellini SA, Al Shaikh O. Characteristics and Factors Related to Eyelid Basal Cell Carcinoma in Saudi Arabia. Middle East Afr J Ophthalmol. 2018 Apr-Jun;25(2):96-102. - PMC - PubMed

Publication types

LinkOut - more resources